Clinical Trial Update: Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dual therapy with Anlotinib and Niraparib for platinum-resistant recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Niraparib (Niraparib)

Snippet

Sponsor: Jihong Liu | Conditions: Platinum-resistant Ovarian Cancer | Phase 2 | Status: UNKNOWN